Outcome | Group | Coefficient (β/ IRR) | P value | Adjusted mean | SE |
---|---|---|---|---|---|
MCS (SF-12v2) | Controls (ref.) | Â | Â | 47.44 | 0.59 |
  (n = 19,481) | COPD Risk | β: − 3.75 | < 0.000 | 43.70 | 0.59 |
PCS (SF-12v2) | Controls (ref.) | Â | Â | 47.01 | 0.49 |
  (n = 19,481) | COPD Risk | β: −4.28 | < 0.000 | 42.73 | 0.50 |
Health utility (EQ-5D) | Controls (ref.) | Â | Â | 0.86 | 0.01 |
  (n = 19,481) | COPD Risk | β: −0.08 | < 0.000 | 0.61 | 0.01 |
ER visits | Controls (ref.) | Â | Â | 0.41 | 0.03 |
  (n = 18,616) | COPD Risk | IRR: 1.71 | < 0.000 | 0.70 | 0.06 |
Hospitalisations | Controls (ref.) | Â | Â | 0.11 | 0.01 |
  (n = 18,616) | COPD Risk | IRR: 2.92 | < 0.000 | 0.31 | 0.04 |
HCP visits | Controls (ref.) | Â | Â | 2.16 | 0.11 |
  (n = 18,616) | COPD Risk | IRR: 1.31 | < 0.000 | 2.83 | 0.15 |
Respiratory specialist visits | Controls (ref.) | Â | Â | 0.17 | 0.03 |
  (n = 18,616) | COPD Risk | IRR: 1.38 | 0.008 | 0.23 | 0.04 |
Absenteeism | Controls (ref.) | Â | Â | 4.26 | 0.58 |
  (n = 13,658) | COPD Risk | IRR: 2.46 | < 0.000 | 10.48 | 1.55 |
Presenteeism | Controls (ref.) | Â | Â | 21.57 | 1.52 |
  (n = 13,658) | COPD Risk | IRR: 1.74 | < 0.000 | 37.51 | 2.85 |
Overall work impairment | Controls (ref.) | Â | Â | 24.10 | 1.66 |
  (n = 13,658) | COPD Risk | IRR: 1.74 | < 0.000 | 42.01 | 3.13 |
Activity impairment | Controls (ref.) | Â | Â | 20.85 | 1.12 |
  (n = 18,616) | COPD Risk | IRR: 1.71 | < 0.000 | 35.69 | 2.02 |